Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

Recs

0
Player Avatar pchop123 (79.86) Submitted: 3/7/2013 9:01:30 PM : Outperform Start Price: $2.04 NVAX Score: +4.16

momentum & not done yet

Featured Broker Partners


Advertisement